Molecular insights into psychedelic drug action

A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical re...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurochemistry Vol. 162; no. 1; pp. 24 - 38
Main Authors Slocum, Samuel T., DiBerto, Jeffrey F., Roth, Bryan L.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.07.2022
Subjects
Drugs
G protein‐coupled receptors (GPCR)
Health care
LSD
Lysergic acid diethylamide
Lysergide
Mental health
Mescaline
neurons
Psilocybin
Psychedelic drugs
psychedelics
serotonin
special issue
psychedelics
special issue
serotonin
neurons
G protein-coupled receptors (GPCR)
Online AccessGet full text

Cover

Abstract A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the United States Food and Drug Administration's designation of psilocybin as a “Breakthrough Therapy” for treatment‐resistant depression, a new path has been forged for the conveyance of psychedelics to the clinic. Essential to the further development of such applications, however, is a clearer understanding of how these drugs exert their effects at the molecular level. Here we review the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms. In this article we review the current understanding of the molecular details of psychedelic drug effects. We provide information from the atomic to the cellular level and integrate this information into a model of psychedelic drug actions.
AbstractList A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the United States Food and Drug Administration's designation of psilocybin as a "Breakthrough Therapy" for treatment-resistant depression, a new path has been forged for the conveyance of psychedelics to the clinic. Essential to the further development of such applications, however, is a clearer understanding of how these drugs exert their effects at the molecular level. Here we review the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms.
A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the United States Food and Drug Administration's designation of psilocybin as a “Breakthrough Therapy” for treatment‐resistant depression, a new path has been forged for the conveyance of psychedelics to the clinic. Essential to the further development of such applications, however, is a clearer understanding of how these drugs exert their effects at the molecular level. Here we review the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms. In this article we review the current understanding of the molecular details of psychedelic drug effects. We provide information from the atomic to the cellular level and integrate this information into a model of psychedelic drug actions.
Abstract A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the United States Food and Drug Administration's designation of psilocybin as a “Breakthrough Therapy” for treatment‐resistant depression, a new path has been forged for the conveyance of psychedelics to the clinic. Essential to the further development of such applications, however, is a clearer understanding of how these drugs exert their effects at the molecular level. Here we review the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms. image
Author DiBerto, Jeffrey F.
Roth, Bryan L.
Slocum, Samuel T.
Author_xml – sequence: 1
  givenname: Samuel T.
  orcidid: 0000-0001-5942-4367
  surname: Slocum
  fullname: Slocum, Samuel T.
  organization: University of North Carolina at Chapel Hill School of Medicine
– sequence: 2
  givenname: Jeffrey F.
  orcidid: 0000-0002-8227-2071
  surname: DiBerto
  fullname: DiBerto, Jeffrey F.
  organization: University of North Carolina at Chapel Hill School of Medicine
– sequence: 3
  givenname: Bryan L.
  orcidid: 0000-0002-0561-6520
  surname: Roth
  fullname: Roth, Bryan L.
  email: bryan_roth@med.unc.edu
  organization: University of North Carolina at Chapel Hill School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34797943$$D View this record in MEDLINE/PubMed
BookMark eNp10LtOwzAUBmALFdELDLwAisQCQ9rjS2xnRBVXFVhgthLHaVOlcbETob49LikMSNiDPXz6dc4_RoPGNgahcwxTHM5s3egpThIGR2iEmcAxw0k6QCMAQmIKjAzR2Ps1AOaM4xM0pEykImV0hGbPtja6qzMXVY2vlqvWh09ro63f6ZUpTF3pqHDdMsp0W9nmFB2XWe3N2eGdoPe727f5Q7x4vX-c3yxiTaWEWML-MklKI3VOijKlQgjIRZFloAtOBcOCUJ3mmpecg-EpBynC7CQBglM6QVd97tbZj874Vm0qr01dZ42xnVeEh-VkknAR6OUfurada8J0QUmSSEEYBHXdK-2s986UauuqTeZ2CoPat6hCi-q7xWAvDoldvjHFr_ypLYBZDz6r2uz-T1JPL_M-8gv38Hn9
CitedBy_id crossref_primary_10_1021_acsptsci_2c00177
crossref_primary_10_1002_1873_3468_14904
crossref_primary_10_1016_j_neubiorev_2022_105000
crossref_primary_10_1007_s00213_022_06297_0
crossref_primary_10_1152_ajpcell_00397_2022
crossref_primary_10_1021_acs_chemrev_3c00375
crossref_primary_10_1016_j_neuropharm_2024_110030
crossref_primary_10_7717_peerj_17517
crossref_primary_10_3390_ijms232214148
crossref_primary_10_1038_s41380_024_02477_w
crossref_primary_10_3390_ph15050640
crossref_primary_10_1016_j_neuropharm_2023_109422
crossref_primary_10_1021_acschemneuro_1c00815
crossref_primary_10_1021_acs_biochem_1c00812
crossref_primary_10_3389_fphar_2023_1239159
crossref_primary_10_3390_molecules28176375
crossref_primary_10_1016_j_bpsc_2024_01_007
crossref_primary_10_1021_acs_jmedchem_3c01178
crossref_primary_10_7759_cureus_30214
crossref_primary_10_1021_acs_biochem_3c00598
crossref_primary_10_3389_fnmol_2021_790213
Cites_doi 10.1126/science.1232808
10.1038/s41594‐018‐0180‐z
10.1016/S0021‐9258(18)53442‐6
10.1016/j.neuron.2007.01.008
10.1038/nature19112
10.1073/pnas.87.6.2187
10.1038/nsmb.3014
10.1021/cn400216u
10.1016/j.celrep.2021.109836
10.1074/jbc.M805705200
10.1146/annurev‐biochem‐061620‐044044
10.1016/j.neuron.2021.07.017
10.1523/JNEUROSCI.17-08-02785.1997
10.1016/j.neuropharm.2007.03.013
10.1124/mol.52.2.259
10.1016/S0163‐7258(98)00019‐9
10.1016/0306‐4522(91)90128‐B
10.1016/0028‐3908(84)90244‐2
10.1016/j.cell.2016.12.033
10.1016/j.bcp.2020.114251
10.1016/S0091‐3057(01)00720‐1
10.1016/0306‐4522(87)90327‐7
10.1016/j.cell.2018.01.001
10.1016/0024‐3205(87)90621‐7
10.1002/j.1460-2075.1988.tb03308.x
10.1124/mol.63.5.961
10.2174/1568026023393796
10.3109/10409238.2010.516741
10.1016/S0893‐133X(01)00405‐5
10.1016/S0306‐4522(02)00146‐X
10.1002/syn.890210205
10.1126/science.1190287
10.1016/0006‐8993(85)90857‐1
10.1016/0165-3806(91)90236-C
10.1016/0306‐9877(91)90077‐C
10.1016/j.celrep.2018.05.022
10.1074/jbc.M301905200
10.1002/(SICI)1096‐9861(19990628)409:2<187:AID‐CNE2>3.0.CO;2‐P
10.1016/j.neuron.2021.06.008
10.1016/j.neures.2014.03.006
10.1021/acschemneuro.9b00528
10.1016/j.neures.2011.07.1824
10.1016/j.expneurol.2021.113778
10.1002/(SICI)1098‐2396(199709)27:1<79:AID‐SYN8>3.0.CO;2‐A
10.1523/JNEUROSCI.3007-12.2013
10.1002/syn.10006
10.1016/j.bbrc.2020.08.022
10.1126/science.aat8078
10.1177/107385849900500414
10.1161/CIRCRESAHA.110.231308
10.1016/0028‐3908(84)90017‐0
10.1002/syn.890090311
10.1073/pnas.1104807108
10.1016/0169‐328X(94)90015‐9
10.1016/0006‐2952(84)90699‐3
10.1016/j.cell.2020.03.020
10.1016/0922‐4106(91)90093‐W
10.1016/j.ebiom.2016.08.049
10.7554/eLife.35082
10.1016/S0306‐4522(03)00589‐X
10.1093/ijnp/pyy047
10.1016/S0006‐3223(98)00132‐2
10.1046/j.1471‐4159.1997.68051998.x
10.1002/(SICI)1097‐4652(199806)175:3<341:AID‐JCP12>3.0.CO;2‐8
10.1073/pnas.0905884106
10.1073/pnas.0600585103
10.1016/0024‐3205(84)90436‐3
10.1111/j.1460‐9568.2005.03968.x
10.1177/0269881114555249
10.1074/mcp.M113.036558
10.1016/0166‐4328(96)00070‐8
10.1073/pnas.87.3.928
10.1126/scisignal.aav0320
10.1111/j.1471-4159.1987.tb02444.x
10.1038/tp.2011.35
10.1124/mol.58.5.877
10.1016/S0021‐9258(20)79672‐9
10.1124/jpet.106.104463
10.1016/S0169‐328X(03)00029‐9
10.1124/jpet.115.229765
10.1124/jpet.117.239905
10.1038/s41386‐020‐00883‐6
10.1016/0169‐328X(92)90005‐V
10.1016/j.neuropharm.2017.01.034
10.1124/mol.109.061440
10.1074/jbc.M501696200
10.1046/j.1471‐4159.1996.67062521.x
10.1021/acs.jmedchem.6b00748
10.1016/0014‐2999(87)90373‐6
10.1016/S0223-5234(99)80094-4
10.1146/annurev.med.60.042307.110802
10.1152/ajprenal.1999.276.6.F922
10.1073/pnas.95.2.735
10.1038/272168a0
10.3390/ijms22020835
10.1038/s41589‐020‐0535‐8
10.1016/j.cell.2020.08.024
10.1038/171387a0
10.1016/0306‐4522(90)90099‐P
10.1097/00001756‐199812010‐00024
10.1016/j.tins.2020.11.008
10.1016/S0021‐9258(20)85329‐0
10.1016/S1043-9471(05)80049-7
10.1523/JNEUROSCI.1665-10.2010
10.1016/j.neuron.2016.01.040
10.1074/jbc.M404673200
10.1073/pnas.0708862105
10.1016/S0028‐3908(97)00051‐8
10.1038/nature08506
10.1111/j.1471-4159.2006.04173.x
10.1074/jbc.M312106200
10.1523/JNEUROSCI.1090‐09.2009
10.1097/NMD.0000000000000113
10.1016/j.euroneuro.2016.05.001
10.1126/science.1232807
10.1098/rspb.1983.0093
10.1016/j.euroneuro.2019.10.013
10.1016/0005‐2736(95)00073‐C
10.1111/j.1749‐6632.1998.tb10180.x
10.1016/0166‐4328(96)00093‐9
10.1038/s41598-021-96736-3
10.1126/science.1103492
10.1021/acsptsci.0c00176
10.1124/mol.54.1.94
10.1124/jpet.102.042184
10.1046/j.1471-4159.1999.0722206.x
10.1124/pr.115.011478
10.1016/j.cell.2021.01.027
10.1111/j.1471‐4159.1983.tb11817.x
10.1016/j.pharmthera.2003.11.002
10.1016/0014‐2999(85)90577‐1
10.1016/0006-8993(90)90502-3
ContentType Journal Article
Copyright 2021 International Society for Neurochemistry
2021 International Society for Neurochemistry.
Copyright © 2022 International Society for Neurochemistry
Copyright_xml – notice: 2021 International Society for Neurochemistry
– notice: 2021 International Society for Neurochemistry.
– notice: Copyright © 2022 International Society for Neurochemistry
DBID NPM
AAYXX
CITATION
7QR
7TK
7U7
7U9
8FD
C1K
FR3
H94
P64
7X8
DOI 10.1111/jnc.15540
DatabaseName PubMed
CrossRef
Chemoreception Abstracts
Neurosciences Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList PubMed

Virology and AIDS Abstracts
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1471-4159
EndPage 38
ExternalDocumentID 10_1111_jnc_15540
34797943
JNC15540
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: R37 DA045657
– fundername: NIMH NIH HHS
  grantid: R01 MH112205
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
24P
29L
2WC
31~
33P
36B
3SF
4.4
41~
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAYJJ
AAZKR
ABCQN
ABCUV
ABEML
ABIVO
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOD
ACGOF
ACIWK
ACMXC
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GAKWD
GODZA
GX1
H.X
HF~
HGLYW
HH5
HVGLF
HZI
HZ~
IH2
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MVM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
TWZ
UB1
V8K
VH1
W8V
W99
WBKPD
WIH
WIJ
WIK
WIN
WNSPC
WOHZO
WOW
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XJT
YFH
YNH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
NPM
AAYXX
CITATION
7QR
7TK
7U7
7U9
8FD
C1K
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c3880-808080482fe8cb2df937770b7daa0cd63741723c9bc6f660e6960874712502193
IEDL.DBID DR2
ISSN 0022-3042
IngestDate Thu Jul 25 11:24:52 EDT 2024
Thu Oct 10 22:04:31 EDT 2024
Fri Aug 23 02:03:47 EDT 2024
Sat Sep 28 08:19:48 EDT 2024
Sat Aug 24 00:55:43 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords psychedelics
special issue
serotonin
neurons
G protein-coupled receptors (GPCR)
Language English
License 2021 International Society for Neurochemistry.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3880-808080482fe8cb2df937770b7daa0cd63741723c9bc6f660e6960874712502193
Notes Funding information
This Review is part of the special issue
There are no funders to report for this Review article.
Psychedelics and Neurochemistry
.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-8227-2071
0000-0001-5942-4367
0000-0002-0561-6520
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jnc.15540
PMID 34797943
PQID 2682587240
PQPubID 31528
PageCount 15
ParticipantIDs proquest_miscellaneous_2600285567
proquest_journals_2682587240
crossref_primary_10_1111_jnc_15540
pubmed_primary_34797943
wiley_primary_10_1111_jnc_15540_JNC15540
PublicationCentury 2000
PublicationDate July 2022
PublicationDateYYYYMMDD 2022-07-01
PublicationDate_xml – month: 07
  year: 2022
  text: July 2022
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
PublicationTitle Journal of neurochemistry
PublicationTitleAlternate J Neurochem
PublicationYear 2022
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References 2019; 11
2002; 277
2020; 16
1996; 73
2008; 105
1997; 280
2003; 278
2014; 81–82
1980; 255
2001; 42
2018; 7
2018; 172
1987; 41
1995; 25
1997; 52
2011; 71
2019; 26
1978; 272
1995; 21
2019; 29
2014; 13
1998; 95
2017; 168
2010; 30
1996; 67
1998; 284
1987; 49
2021; 46
1986; 238
1990; 524
2010; 329
2011; 1
2021; 44
1990; 37
1990; 38
2002; 72
2009; 60
1993; 43
2007; 320
2002; 2
1997; 27
2013; 340
2018; 23
2004; 306
2018; 21
1996; 10
2016; 11
2010; 45
1990; 3
2004; 279
1995; 48
1995; 47
1997; 36
1984; 33
1984; 35
2009; 462
1999; 34
2016; 26
1953; 87
2006; 103
1998; 9
2009; 106
1991; 207
1998; 79
1999; 409
1991; 58
2021; 22
2002; 113
1984; 23
2000; 293
2005; 21
1994; 27
1992; 14
2019; 364
2003; 111
1998; 44
2017; 117
2021; 37
1990; 87
2014; 5
1983; 220
2000; 58
1991; 40
1997; 17
2017; 361
2016; 357
2020; 531
1998; 54
2014; 202
2003; 122
2016; 89
2004; 101
2021; 9
2021; 109
2010; 77
2021; 4
1991; 35
2021; 343
2006; 99
2020; 181
2020; 182
1997; 68
1994; 45
2021; 184
1985; 346
2007; 52
2007; 53
1993; 268
1991; 9
1999; 5
2016; 59
2021; 90
2008; 284
2009; 29
1998; 175
2021; 14
2005; 280
2002; 26
2011; 109
1993; 19
1987; 134
2011; 108
1987; 21
2003; 304
2015; 29
2021; 11
2013; 33
2016; 537
1995; 1236
2015; 22
1988; 7
1985; 234
1983; 41
1985; 115
1999; 276
1999; 72
1998; 861
2003; 63
2016; 68
1967
e_1_2_9_75_1
e_1_2_9_98_1
e_1_2_9_52_1
e_1_2_9_79_1
e_1_2_9_94_1
e_1_2_9_10_1
e_1_2_9_56_1
e_1_2_9_33_1
e_1_2_9_90_1
e_1_2_9_71_1
e_1_2_9_103_1
e_1_2_9_126_1
e_1_2_9_149_1
e_1_2_9_107_1
e_1_2_9_122_1
e_1_2_9_145_1
Choudhary M. S. (e_1_2_9_25_1) 1995; 47
e_1_2_9_14_1
e_1_2_9_141_1
Abramson H. A. (e_1_2_9_3_1) 1967
e_1_2_9_37_1
e_1_2_9_18_1
e_1_2_9_41_1
e_1_2_9_87_1
e_1_2_9_22_1
e_1_2_9_45_1
e_1_2_9_68_1
e_1_2_9_83_1
Garnovskaya M. N. (e_1_2_9_39_1) 1995; 48
e_1_2_9_6_1
e_1_2_9_119_1
e_1_2_9_60_1
e_1_2_9_2_1
Choudhary M. S. (e_1_2_9_24_1) 1993; 43
e_1_2_9_138_1
e_1_2_9_111_1
e_1_2_9_115_1
e_1_2_9_26_1
e_1_2_9_49_1
e_1_2_9_130_1
e_1_2_9_30_1
e_1_2_9_53_1
e_1_2_9_99_1
e_1_2_9_72_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_57_1
e_1_2_9_95_1
e_1_2_9_76_1
e_1_2_9_91_1
e_1_2_9_102_1
e_1_2_9_148_1
e_1_2_9_129_1
e_1_2_9_144_1
e_1_2_9_106_1
Teitler M. (e_1_2_9_131_1) 1990; 38
e_1_2_9_125_1
e_1_2_9_15_1
e_1_2_9_38_1
Nakaki T. (e_1_2_9_81_1) 1985; 234
e_1_2_9_140_1
e_1_2_9_121_1
e_1_2_9_19_1
e_1_2_9_42_1
e_1_2_9_88_1
e_1_2_9_61_1
e_1_2_9_46_1
e_1_2_9_84_1
e_1_2_9_23_1
e_1_2_9_65_1
e_1_2_9_80_1
e_1_2_9_5_1
e_1_2_9_114_1
e_1_2_9_137_1
Florian J. A. (e_1_2_9_36_1) 1998; 284
e_1_2_9_118_1
e_1_2_9_133_1
Toth M. (e_1_2_9_134_1) 1994; 45
e_1_2_9_9_1
e_1_2_9_27_1
e_1_2_9_69_1
e_1_2_9_110_1
e_1_2_9_31_1
e_1_2_9_50_1
e_1_2_9_73_1
e_1_2_9_35_1
e_1_2_9_77_1
e_1_2_9_96_1
e_1_2_9_12_1
e_1_2_9_92_1
e_1_2_9_109_1
e_1_2_9_101_1
e_1_2_9_128_1
e_1_2_9_124_1
e_1_2_9_147_1
e_1_2_9_120_1
e_1_2_9_16_1
e_1_2_9_58_1
e_1_2_9_143_1
e_1_2_9_62_1
e_1_2_9_89_1
e_1_2_9_43_1
e_1_2_9_66_1
e_1_2_9_85_1
e_1_2_9_8_1
e_1_2_9_4_1
e_1_2_9_113_1
e_1_2_9_117_1
e_1_2_9_136_1
e_1_2_9_28_1
e_1_2_9_47_1
e_1_2_9_132_1
e_1_2_9_74_1
e_1_2_9_51_1
e_1_2_9_78_1
e_1_2_9_13_1
e_1_2_9_32_1
Kristiansen K. (e_1_2_9_64_1) 2000; 293
e_1_2_9_97_1
e_1_2_9_93_1
e_1_2_9_70_1
Roth B. (e_1_2_9_112_1) 1986; 238
e_1_2_9_127_1
e_1_2_9_100_1
e_1_2_9_123_1
e_1_2_9_146_1
e_1_2_9_17_1
e_1_2_9_59_1
e_1_2_9_142_1
Roth B. L. (e_1_2_9_108_1) 1990; 3
Johnson M. L. (e_1_2_9_54_1) 1994; 45
e_1_2_9_63_1
e_1_2_9_40_1
e_1_2_9_21_1
e_1_2_9_67_1
e_1_2_9_44_1
e_1_2_9_86_1
e_1_2_9_7_1
Johnson M. P. (e_1_2_9_55_1) 1993; 19
Branchek T. (e_1_2_9_20_1) 1990; 38
e_1_2_9_82_1
Roth B. (e_1_2_9_105_1) 1996; 10
e_1_2_9_139_1
Roth B. L. (e_1_2_9_104_1) 1997; 280
e_1_2_9_116_1
e_1_2_9_135_1
e_1_2_9_48_1
e_1_2_9_29_1
References_xml – volume: 1
  year: 2011
  article-title: Schizophrenia risk gene CAV1 is both pro‐psychotic and required for atypical antipsychotic drug actions in vivo
  publication-title: Translational Psychiatry
– volume: 175
  start-page: 341
  year: 1998
  end-page: 347
  article-title: Signaling pathways mediating induction of the early response genes prostaglandin G/H synthase‐2 and EGR‐1 by serotonin via 5‐HT2A receptors
  publication-title: Journal of Cellular Physiology
– volume: 181
  start-page: 24
  year: 2020
  end-page: 28
  article-title: Psychedelic psychiatry's brave new world
  publication-title: Cell
– volume: 60
  start-page: 355
  year: 2009
  end-page: 366
  article-title: The expanded biology of serotonin
  publication-title: Annual Review of Medicine
– volume: 25
  start-page: 366
  year: 1995
  article-title: Integrated methods for the construction of three‐dimensional models and computational probing of structure‐function relations in g protein‐coupled receptors
  publication-title: Methods in Neurosciences
– volume: 207
  start-page: 169
  year: 1991
  end-page: 172
  article-title: Chronic mianserin treatment decreases 5‐HT2 receptor binding without altering 5‐HT2 receptor mRNA levels
  publication-title: European Journal of Pharmacology
– volume: 238
  start-page: 480
  year: 1986
  end-page: 485
  article-title: 5‐hydroxytryptamine2 receptors coupled to phospholipase‐C in rat aorta ‐ modulation of phosphoinositide turnover by phorbol ester
  publication-title: Journal of Pharmacology and Experimental Therapeutics
– volume: 67
  start-page: 2521
  year: 1996
  end-page: 2531
  article-title: Characterisation of human 5‐hydroxytryptamine2A and 5‐hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH‐SY5Y: Comparative stimulation by hallucinogenic drugs
  publication-title: Journal of Neurochemistry
– volume: 87
  start-page: 2187
  year: 1990
  end-page: 2191
  article-title: Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 340
  start-page: 615
  year: 2013
  end-page: 619
  article-title: Structural features for functional selectivity at serotonin receptors
  publication-title: Science
– volume: 63
  start-page: 961
  year: 2003
  end-page: 972
  article-title: The interaction of a constitutively active arrestin with the arrestin‐insensitive 5‐HT(2A) receptor induces agonist‐independent internalization
  publication-title: Molecular Pharmacology
– volume: 531
  start-page: 609
  year: 2020
  end-page: 614
  article-title: Differential signaling signatures evoked by DOI versus lisuride stimulation of the 5‐HT2A receptor
  publication-title: Biochemical and Biophysical Research Communications
– volume: 29
  start-page: 7124
  year: 2009
  end-page: 7136
  article-title: PSD‐95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors
  publication-title: Journal of Neuroscience
– volume: 52
  start-page: 1671
  year: 2007
  end-page: 1677
  article-title: Role of G(q) protein in behavioral effects of the hallucinogenic drug 1‐(2,5‐dimethoxy‐4‐iodophenyl)‐2‐aminopropane
  publication-title: Neuropharmacology
– volume: 10
  start-page: 773
  year: 1996
  article-title: Highly conserved aromatic residues are essential for agonist efficacy at 5‐HT2A receptors
  publication-title: The FASEB Journal
– volume: 35
  start-page: 2505
  year: 1984
  end-page: 2511
  article-title: Evidence for 5‐HT2 involvement in the mechanism of action of hallucinogenic agents
  publication-title: Life Sciences
– volume: 537
  start-page: 185
  year: 2016
  end-page: 190
  article-title: Structure‐based discovery of opioid analgesics with reduced side effects
  publication-title: Nature
– volume: 2
  start-page: 507
  year: 2002
  end-page: 528
  article-title: Molecular biology of serotonin receptors structure and function at the molecular level
  publication-title: Current Topics in Medicinal Chemistry
– volume: 26
  start-page: 634
  issue: 5
  year: 2002
  end-page: 642
  article-title: A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain
  publication-title: Neuropsychopharmacology
– volume: 9
  start-page: 2535
  year: 2021
  end-page: 2544.e4
  article-title: Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
  publication-title: Neuron
– volume: 108
  start-page: 18488
  year: 2011
  end-page: 18493
  article-title: Discovery of beta‐arrestin‐biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 95
  start-page: 735
  year: 1998
  end-page: 740
  article-title: 5‐hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 320
  start-page: 1
  year: 2007
  end-page: 13
  article-title: Functional selectivity and classical concepts of quantitative pharmacology
  publication-title: Journal of Pharmacology and Experimental Therapeutics
– volume: 87
  start-page: 928
  year: 1990
  end-page: 932
  article-title: The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 278
  start-page: 21901
  year: 2003
  end-page: 21908
  article-title: A direct interaction of PSD‐95 with 5‐HT2A serotonin receptors regulates receptor trafficking and signal transduction
  publication-title: The Journal of Biological Chemistry
– volume: 40
  start-page: 399
  year: 1991
  end-page: 412
  article-title: 5‐Hydroxytryptamine2 and 5‐hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex
  publication-title: Neuroscience
– volume: 33
  start-page: 2807
  year: 1984
  end-page: 2811
  article-title: Evidence for functional 5‐HT2 receptor sites on human blood platelets
  publication-title: Biochemical Pharmacology
– volume: 3
  start-page: 427
  year: 1990
  end-page: 433
  article-title: Regulation of 5‐HT2 and 5‐HT1C serotonin receptor levels
  publication-title: Methodology and Mechanisms. Neuropsychopharmacology
– volume: 16
  start-page: 841
  year: 2020
  end-page: 849
  article-title: TRUPATH, an open‐source biosensor platform for interrogating the GPCR transducerome
  publication-title: Nature Chemical Biology
– volume: 109
  start-page: 205
  year: 2011
  end-page: 216
  article-title: Biased ligands for better cardiovascular drugs: Dissecting G‐protein‐coupled receptor pharmacology
  publication-title: Circulation Research
– volume: 524
  start-page: 139
  year: 1990
  end-page: 143
  article-title: Localization of the mRNA for the 5‐HT2 receptor by in situ hybridization histochemistry
  publication-title: Brain Research
– volume: 87
  start-page: 387
  year: 1953
  end-page: 406
  article-title: Dendritic organization in the neurons of the visual and motor cortices of the cat
  publication-title: Journal of Anatomy
– volume: 21
  start-page: 1299
  year: 2005
  end-page: 1303
  article-title: Short‐term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus
  publication-title: The European Journal of Neuroscience
– volume: 42
  start-page: 151
  year: 2001
  end-page: 163
  article-title: Altered dendritic spine density in animal models of depression and in response to antidepressant treatment
  publication-title: Synapse (New York, N. Y.)
– volume: 5
  start-page: 254
  year: 1999
  end-page: 262
  article-title: Activation is hallucinogenic and antagonism is therapeutic: Role of 5‐HT receptors in atypical antipsychotic drug actions
  publication-title: The Neuroscientist
– volume: 364
  start-page: eaat8078
  year: 2019
  article-title: Sustained rescue of prefrontal circuit dysfunction by antidepressant‐induced spine formation
  publication-title: Science
– volume: 26
  start-page: 121
  year: 2019
  end-page: 128
  article-title: Structures of the 5‐HT2A receptor in complex with the antipsychotics risperidone and zotepine
  publication-title: Nature Structural & Molecular Biology
– volume: 14
  start-page: eaav0320
  year: 2021
  article-title: Biased ligands at opioid receptors: Current status and future directions
  publication-title: Science Signaling
– volume: 182
  start-page: 1574
  year: 2020
  end-page: 1588.e1519
  article-title: Structure of A hallucinogen activated Gq‐coupled 5‐HT2A serotonin receptor
  publication-title: Cell
– volume: 53
  start-page: 439
  year: 2007
  end-page: 452
  article-title: Hallucinogens recruit specific cortical 5‐HT(2A) receptor‐mediated signaling pathways to affect behavior
  publication-title: Neuron
– volume: 184
  start-page: 931
  year: 2021
  end-page: 942.e18
  article-title: Structural insights into the human D1 and D2 dopamine receptor signaling complexes
  publication-title: Cell
– volume: 46
  start-page: 537
  year: 2021
  end-page: 544
  article-title: Acute dose‐dependent effects of lysergic acid diethylamide in a double‐blind placebo‐controlled study in healthy subjects
  publication-title: Neuropsychopharmacology
– volume: 45
  start-page: 277
  year: 1994
  end-page: 286
  article-title: Species variations in transmembrane region V of the 5‐Hydroxytrptamine type 2A receptor alter the structure‐activity relationship of certain ergolines and tryptamines
  publication-title: Molecular Pharmacology
– volume: 36
  start-page: 589
  year: 1997
  end-page: 599
  article-title: Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells
  publication-title: Neuropharmacology
– volume: 340
  start-page: 610
  year: 2013
  end-page: 614
  article-title: Structural basis for molecular recognition at serotonin receptors
  publication-title: Science
– volume: 276
  start-page: F922
  year: 1999
  end-page: 930
  article-title: Serotonin 5‐HT2A receptor induces TGF‐beta1 expression in mesangial cells via ERK: Proliferative and fibrotic signals
  publication-title: American Journal of Physiology
– volume: 111
  start-page: 182
  year: 2003
  end-page: 188
  article-title: Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration
  publication-title: Molecular Brain Research
– volume: 293
  start-page: 735
  year: 2000
  end-page: 746
  article-title: A highly conserved aspartic acid (D155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5‐HT2A serotonin receptor but does not participate in activation via a ‘salt‐bridge disruption’ mechanism
  publication-title: Journal of Pharmacology and Experimental Therapeutics
– volume: 21
  start-page: 123
  year: 1995
  end-page: 130
  article-title: Protein kinase C inhibitors enhance the 5‐HT2A receptor‐mediated excitatory effects of serotonin on interneurons in rat piriform cortex
  publication-title: Synapse (New York, N. Y.)
– volume: 72
  start-page: 2206
  year: 1999
  end-page: 2214
  article-title: Structure and function of the third intracellular loop of the 5‐hydroxytryptamine(2A) receptor: The third intracellular loop is alpha‐helical and binds purified arrestins
  publication-title: Journal of Neurochemistry
– volume: 54
  start-page: 94
  year: 1998
  end-page: 104
  article-title: Effector pathway‐dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist‐directed trafficking of receptor stimulus
  publication-title: Molecular Pharmacology
– volume: 361
  start-page: 441
  year: 2017
  end-page: 453
  article-title: Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N‐(2‐Hydroxybenzyl)‐2,5‐dimethoxy‐4‐cyanophenylethylamine (25CN‐NBOH), a highly selective and brain‐penetrant 5‐HT2A receptor agonist
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 22
  start-page: 362
  year: 2015
  end-page: U328
  article-title: PRESTO‐Tango as an open‐source resource for interrogation of the druggable human GPCRome
  publication-title: Nature Structural & Molecular Biology
– volume: 122
  start-page: 907
  year: 2003
  end-page: 920
  article-title: The PDZ‐binding domain is essential for the dendritic targeting of 5‐HT(2A) serotonin receptors in cortical pyramidal neurons in vitro
  publication-title: Neuroscience
– volume: 117
  start-page: 93
  year: 2017
  end-page: 105
  article-title: Receptor‐stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines
  publication-title: Neuropharmacology
– volume: 268
  start-page: 4625
  year: 1993
  end-page: 4636
  article-title: A mutation‐induced activated state of the beta 2‐adrenergic receptor. Extending the ternary complex model
  publication-title: The Journal of Biological Chemistry
– volume: 255
  start-page: 7108
  year: 1980
  end-page: 7117
  article-title: A ternary complex model explains the agonist‐specific binding properties of the adenylate cyclase‐coupled beta‐adrenergic receptor
  publication-title: The Journal of Biological Chemistry
– volume: 29
  start-page: 1453
  year: 2019
  end-page: 1463
  article-title: Serotonin 5‐HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Galphai1‐proteins
  publication-title: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
– volume: 861
  start-page: 104
  year: 1998
  end-page: 110
  article-title: Pleiotropic behavior of 5‐HT2A and 5‐HT2C receptor agonists
  publication-title: Annals of the New York Academy of Sciences
– volume: 77
  start-page: 327
  year: 2010
  end-page: 338
  article-title: Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5‐hydroxytryptamine 2A serotonin receptor functional selectivity
  publication-title: Molecular Pharmacology
– volume: 9
  start-page: 235
  year: 1991
  end-page: 237
  article-title: Changes in dendritic spine morphology in response to increased availability of monoamines in rat medial prefrontal cortex
  publication-title: Synapse (New York, N. Y.)
– year: 1967
– volume: 284
  start-page: 346
  year: 1998
  end-page: 355
  article-title: Integration of mitogen‐activated protein kinase kinase activation in vascular 5‐hydroxytryptamine2A receptor signal transduction
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 134
  start-page: 373
  year: 1987
  end-page: 375
  article-title: Non‐serotonergic [3H]‐ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endings
  publication-title: European Journal of Pharmacology
– volume: 26
  start-page: 1327
  year: 2016
  end-page: 1337
  article-title: Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
  publication-title: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
– volume: 23
  start-page: 993
  year: 1984
  end-page: 996
  article-title: Selective 5‐HT2 antagonists inhibit serotonin‐stimulated phosphatidylinositol metabolism in cerebral cortex
  publication-title: Neuropharmacology
– volume: 5
  start-page: 243
  year: 2014
  end-page: 249
  article-title: Synthesis and structure‐activity relationships of N‐benzyl phenethylamines as 5‐HT2A/2C agonists
  publication-title: ACS Chemical Neuroscience
– volume: 79
  start-page: 231
  year: 1998
  end-page: 257
  article-title: 5‐Hydroxytryptamine2‐family receptors (5‐hydroxytryptamine2A, 5‐ hydroxytryptamine2B, 5‐hydroxytryptamine2C): Where structure meets function
  publication-title: Pharmacology & Therapeutics
– volume: 27
  start-page: 79
  year: 1997
  end-page: 82
  article-title: Serotonin 5‐HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex
  publication-title: Synapse (New York, N. Y.)
– volume: 37
  start-page: 109836
  issue: 3
  year: 2021
  article-title: Prolonged epigenetic and synaptic plasticity alterations following single exposure to a psychedelic in mice
  publication-title: Cell Reports
– volume: 22
  start-page: 835
  year: 2021
  article-title: A single dose of psilocybin increases synaptic density and decreases 5‐HT2A receptor density in the pig brain
  publication-title: International Journal of Molecular Sciences
– volume: 284
  start-page: 5557
  year: 2008
  end-page: 5573
  article-title: Ribosomal S6 kinase 2 directly phosphorylates the 5‐HT2A serotonin receptor thereby modulating 5‐HT2A signaling
  publication-title: The Journal of Biological Chemistry
– volume: 41
  start-page: 84
  year: 1983
  end-page: 93
  article-title: Analytical subcellular fractionation of rat cortex: Resolution of serotonergic nerve endings and receptors
  publication-title: Journal of Neurochemistry
– volume: 23
  start-page: 3170
  year: 2018
  end-page: 3182
  article-title: Psychedelics promote structural and functional neural plasticity
  publication-title: Cell Reports
– volume: 27
  start-page: 315
  year: 1994
  end-page: 319
  article-title: The 5’ flanking region of the serotonin 2 receptor gene directs brain specific expression in transgenic animals
  publication-title: Molecular Brain Research
– volume: 109
  start-page: 2499
  year: 2021
  end-page: 2501
  article-title: The cranial windows of perception
  publication-title: Neuron
– volume: 29
  start-page: 57
  year: 2015
  end-page: 68
  article-title: LSD‐assisted psychotherapy for anxiety associated with a life‐threatening disease: A qualitative study of acute and sustained subjective effects
  publication-title: Journal of Psychopharmacology
– volume: 1236
  start-page: 201
  year: 1995
  end-page: 206
  article-title: Species differences in 5‐HT2A receptors: Cloned pig and rhesus monkey 5‐HT2A receptors reveal conserved transmembrane homology to the human rather than rat sequence
  publication-title: Biochimica Et Biophysica Acta
– volume: 7
  year: 2018
  article-title: Changes in global and thalamic brain connectivity in LSD‐induced altered states of consciousness are attributable to the 5‐HT2A receptor
  publication-title: Elife
– volume: 357
  start-page: 134
  year: 2016
  end-page: 144
  article-title: In vitro characterization of psychoactive substances at rat, mouse, and human trace amine‐associated receptor 1
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 409
  start-page: 187
  year: 1999
  end-page: 209
  article-title: Cellular and subcellular distribution of the serotonin 5‐HT2A receptor in the central nervous system of adult rat
  publication-title: The Journal of Comparative Neurology
– volume: 234
  start-page: 442
  year: 1985
  end-page: 446
  article-title: Phasic and tonic components in 5‐HT2 receptor‐mediated rat aorta contraction: Participation of Ca++ channels and phospholipase C
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 101
  start-page: 131
  year: 2004
  end-page: 181
  article-title: Hallucinogens
  publication-title: Pharmacology & Therapeutics
– volume: 35
  start-page: 17
  year: 1991
  end-page: 22
  article-title: Antidepressants and synaptic plasticity: A hypothesis
  publication-title: Medical Hypotheses
– volume: 462
  start-page: 175
  year: 2009
  end-page: 181
  article-title: Predicting new molecular targets for known drugs
  publication-title: Nature
– volume: 306
  start-page: 1380
  year: 2004
  end-page: 1383
  article-title: The human polyomavirus, JCV, uses serotonin receptors to infect cells
  publication-title: Science
– volume: 14
  start-page: 20
  year: 1992
  end-page: 26
  article-title: The human 5‐HT2 receptor is encoded by a multiple intron‐exon gene
  publication-title: Molecular Brain Research
– volume: 343
  start-page: 113778
  year: 2021
  article-title: Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics
  publication-title: Experimental Neurology
– volume: 68
  start-page: 1998
  year: 1997
  end-page: 2011
  article-title: Identification of an endogenous 5‐hydroxytryptamine2A receptor in NIH‐ 3T3 cells: Agonist‐induced down‐regulation involves decreases in receptor RNA and number
  publication-title: Journal of Neurochemistry
– volume: 68
  start-page: 264
  year: 2016
  end-page: 355
  article-title: Psychedelics
  publication-title: Pharmacological Reviews
– volume: 58
  start-page: 877
  year: 2000
  end-page: 886
  article-title: Differential modes of agonist binding to 5‐Hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5
  publication-title: Molecular Pharmacology
– volume: 346
  start-page: 231
  year: 1985
  end-page: 249
  article-title: Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin‐2 receptors
  publication-title: Brain Research
– volume: 41
  start-page: 1051
  year: 1987
  end-page: 1064
  article-title: Minireview: Multiple mechanisms of serotonergic signal transduction
  publication-title: Life Sciences
– volume: 38
  start-page: 594
  year: 1990
  end-page: 598
  article-title: 4‐[125I]‐(2,5‐dimethoxy)phenylisopropylamine and [3H]‐ketanserin labeling of 5‐hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected witha rat 5HT2 cDNA: Evidence for multiple states and not multiple 5HT2 receptor subtypes
  publication-title: Molecular Pharmacology
– volume: 168
  start-page: e312
  issue: 377–389
  year: 2017
  article-title: Crystal structure of an LSD‐bound human serotonin receptor
  publication-title: Cell
– volume: 13
  start-page: 1273
  year: 2014
  end-page: 1285
  article-title: Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists
  publication-title: Molecular & Cellular Proteomics
– volume: 105
  start-page: 1079
  year: 2008
  end-page: 1084
  article-title: Agonist‐directed signaling of the serotonin 2A receptor depends on beta‐arrestin‐2 interactions in vivo
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 73
  start-page: 183
  year: 1996
  end-page: 186
  article-title: Transcriptional regulation of the 5‐HT2A receptor
  publication-title: Behavioural Brain Research
– volume: 4
  start-page: 533
  year: 2021
  end-page: 542
  article-title: Investigation of the structure‐activity relationships of psilocybin analogues
  publication-title: ACS Pharmacology & Translational Science
– volume: 81–82
  start-page: 11
  year: 2014
  end-page: 20
  article-title: Serotonin 2A receptor regulates microtubule assembly and induces dynamics of dendritic growth cones in rat cortical neurons in vitro
  publication-title: Journal of Neuroscience Research
– volume: 52
  start-page: 259
  year: 1997
  end-page: 266
  article-title: Identification of conserved aromatic residues essential for agonist binding and efficacy at 5‐HT2A receptors
  publication-title: Molecular Pharmacology
– volume: 279
  start-page: 20257
  year: 2004
  end-page: 20266
  article-title: The serotonin 5‐HT2A and 5‐HT2C receptors interact with specific sets of PDZ proteins
  publication-title: The Journal of Biological Chemistry
– volume: 33
  start-page: 10544
  year: 2013
  end-page: 10551
  article-title: Activation of serotonin 2A receptors underlies the psilocybin‐induced effects on alpha oscillations, N170 visual‐evoked potentials, and visual hallucinations
  publication-title: The Journal of Neuroscience: the Official Journal of the Society for Neuroscience
– volume: 49
  start-page: 1833
  year: 1987
  end-page: 1838
  article-title: Characterization of two [3H]‐ketanserin recognition sites in rat striatum
  publication-title: Journal of Neurochemistry
– volume: 37
  start-page: 685
  year: 1990
  end-page: 692
  article-title: The effects of various antidepressant drugs on the fine‐structure of neurons of the cingulate cortex in culture
  publication-title: Neuroscience
– volume: 277
  start-page: 18244
  year: 2002
  article-title: Evidence for a model of agonist‐induced activation of 5‐hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6 (vol 277, pg 11441, 2002)
  publication-title: Journal of Biological Chemistry
– volume: 220
  start-page: 141
  year: 1983
  end-page: 162
  article-title: Operational models of pharmacological agonism
  publication-title: Proceedings of the Royal Society of London. Series B, Biological Sciences
– volume: 23
  start-page: 1223
  year: 1984
  end-page: 1225
  article-title: Aortic recognition sites for serotonin (5HT) are coupled to phospholipase‐c and modulate phosphatidylinositol turnover
  publication-title: Neuropharmacology
– volume: 30
  start-page: 13513
  year: 2010
  end-page: 13524
  article-title: Serotonin, but not N‐methyltryptamines, activates the serotonin 2A receptor via a β‐arrestin2/Src/Akt signaling complex in vivo
  publication-title: The Journal of Neuroscience: the Official Journal of the Society for Neuroscience
– volume: 113
  start-page: 23
  year: 2002
  end-page: 35
  article-title: Similar ultrastructural distribution of the 5‐HT2A serotonin receptor and microtubule‐associated protein MAP1A in cortical dendrites of adult rat
  publication-title: Neuroscience
– volume: 99
  start-page: 1164
  year: 2006
  end-page: 1175
  article-title: Serotonin 5‐HT(2A) receptor activation induces 2‐arachidonoylglycerol release through a phospholipase c‐dependent mechanism
  publication-title: Journal of Neurochemistry
– volume: 11
  start-page: 17690
  year: 2021
  article-title: LSD‐stimulated behaviors in mice require β‐arrestin 2 but not β‐arrestin 1
  publication-title: Scientific Reports
– volume: 279
  start-page: 34614
  year: 2004
  end-page: 34623
  article-title: Caveolin‐1 interacts with 5‐HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq‐coupled protein receptors
  publication-title: The Journal of Biological Chemistry
– volume: 115
  start-page: 1
  year: 1985
  end-page: 9
  article-title: Solubilization of rat brain serotonin‐S2 receptors using CHAPS/salt
  publication-title: European Journal of Pharmacology
– volume: 172
  start-page: e714
  issue: 719–730
  year: 2018
  article-title: 5‐HT2C receptor structures reveal the structural basis of GPCR polypharmacology
  publication-title: Cell
– volume: 48
  start-page: 230
  year: 1995
  end-page: 237
  article-title: 5‐Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation
  publication-title: Molecular Pharmacology
– volume: 11
  start-page: 3860
  issue: 23
  year: 2019
  end-page: 3869
  article-title: DARK classics in chemical neuroscience: NBOMes
  publication-title: ACS Chemical Neuroscience
– volume: 11
  start-page: 262
  year: 2016
  end-page: 277
  article-title: Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain
  publication-title: EBioMedicine
– volume: 9
  start-page: 3897
  year: 1998
  end-page: 3902
  article-title: Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action
  publication-title: NeuroReport
– volume: 59
  start-page: 8381
  year: 2016
  end-page: 8397
  article-title: Mitragynine/Corynantheidine Pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta‐arrestin‐2
  publication-title: Journal of Medicinal Chemistry
– volume: 43
  start-page: 755
  year: 1993
  end-page: 761
  article-title: A single point mutation (Phe340–>Leu340) of a conserved phenylalanine abolishes 4‐[125I]iodo‐(2,5‐dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5‐hydroxytryptamine2 receptors
  publication-title: Molecular Pharmacology
– volume: 44
  start-page: 260
  year: 2021
  end-page: 275
  article-title: A dendrite‐focused framework for understanding the actions of ketamine and psychedelics
  publication-title: Trends in Neurosciences
– volume: 106
  start-page: 19575
  year: 2009
  end-page: 19580
  article-title: Rapid modulation of spine morphology by the 5‐HT2A serotonin receptor through kalirin‐7 signaling
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 272
  start-page: 168
  year: 1978
  end-page: 171
  article-title: Serotonergic component of neuroleptic receptors
  publication-title: Nature
– volume: 7
  start-page: 4135
  year: 1988
  end-page: 4140
  article-title: Structure and functional expression of a cloned rat serotonin 5‐HT‐2 receptor
  publication-title: The EMBO Journal
– volume: 34
  start-page: 441
  year: 1999
  end-page: 447
  article-title: Engineering in a region of bulk tolerance into the 5‐HT2A receptor
  publication-title: European Journal of Medicinal Chemistry
– volume: 280
  start-page: 30741
  year: 2005
  end-page: 30750
  article-title: Interaction of calmodulin with the serotonin 5‐hydroxytryptamine2A receptor. A putative regulator of G protein coupling and receptor phosphorylation by protein kinase C
  publication-title: The Journal of Biological Chemistry
– volume: 90
  start-page: 739
  year: 2021
  end-page: 761
  article-title: Structural insights accelerate the discovery of opioid alternatives
  publication-title: Annual Review of Biochemistry
– volume: 304
  start-page: 229
  year: 2003
  end-page: 237
  article-title: Serotonin 5‐hydroxytryptamine 2A receptor‐coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 182
  start-page: 114251
  year: 2020
  article-title: Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5‐HT2AR through simultaneous use of beta‐arrestin 2 and miniGalphaq bioassays
  publication-title: Biochemical Pharmacology
– volume: 73
  start-page: 59
  year: 1996
  end-page: 62
  article-title: Determination of transcription initiation sites and promoter activity of the human 5‐HT2A receptor gene
  publication-title: Behavioural Brain Research
– volume: 45
  start-page: 1095
  year: 1994
  end-page: 1100
  article-title: Antagonist‐mediated down‐regulation of 5‐hydroxytryptamine type 2 receptor gene expression: Modulation of transcription
  publication-title: Molecular Pharmacology
– volume: 17
  start-page: 2785
  year: 1997
  end-page: 2795
  article-title: 5‐HT2A receptor‐mediated regulation of brain‐derived neurotrophic factor mRNA in the hippocampus and the neocortex
  publication-title: Journal of Neuroscience
– volume: 202
  start-page: 513
  year: 2014
  end-page: 520
  article-title: Safety and efficacy of lysergic acid diethylamide‐assisted psychotherapy for anxiety associated with life‐threatening diseases
  publication-title: The Journal of Nervous and Mental Disease
– volume: 19
  start-page: 1164
  year: 1993
  article-title: The ala/ser242 species variation results in species selectivity with certain substituted ergolines and tryptamines for 5‐HT2 receptors
  publication-title: Society for Neuroscience Abstracts
– volume: 280
  start-page: 576
  year: 1997
  end-page: 583
  article-title: High‐affinity agonist binding is not sufficient for agonist efficacy at 5‐hydroxytryptamine2A receptors: Evidence in favor of a modified ternary complex model
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 329
  start-page: 959
  year: 2010
  end-page: 964
  article-title: mTOR‐dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists
  publication-title: Science
– volume: 47
  start-page: 450
  year: 1995
  end-page: 457
  article-title: Differential ergoline and ergopeptine binding to 5‐hydroxytryptamine2A receptors: Ergolines require an aromatic residue at position 340 for high affinity binding [published erratum appears in Mol Pharmacol 1995 Sep; 48(3):568]
  publication-title: Molecular Pharmacology
– volume: 72
  start-page: 29
  year: 2002
  end-page: 37
  article-title: 5‐HT2A receptor‐stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens
  publication-title: Pharmacology, Biochemistry, and Behavior
– volume: 58
  start-page: 51
  year: 1991
  end-page: 58
  article-title: Developmental regulation of 5‐HT2 and 5‐HT1C messenger‐RNA and receptor levels
  publication-title: Developmental Brain Research
– volume: 71
  start-page: 311
  year: 2011
  end-page: 314
  article-title: Subtype specific roles of serotonin receptors in the spine formation of cortical neurons in vitro
  publication-title: Journal of Neuroscience Research
– volume: 38
  start-page: 604
  year: 1990
  end-page: 609
  article-title: [3H]‐DOB (4‐bromo‐2,5‐dimethoxyphenylisopropylamine) and [3H]‐ketanserin label two affinity states of the cloned human 5‐hydroxytryptamine2 receptor
  publication-title: Molecular Pharmacology
– volume: 44
  start-page: 1128
  year: 1998
  end-page: 1142
  article-title: The molecular biology of serotonin receptors: Therapeutic implications for the interface of mood and psychosis
  publication-title: Biological Psychiatry
– volume: 89
  start-page: 683
  year: 2016
  end-page: 694
  article-title: DREADDs for neuroscientists
  publication-title: Neuron
– volume: 21
  start-page: 926
  year: 2018
  end-page: 931
  article-title: Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics
  publication-title: The International Journal of Neuropsychopharmacology
– volume: 103
  start-page: 4717
  year: 2006
  end-page: 4722
  article-title: p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein‐coupled receptor signaling
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 21
  start-page: 123
  year: 1987
  end-page: 139
  article-title: Serotonin receptors in the human brain‐IV. Autoradiographic mapping of serotonin‐2 receptors
  publication-title: Neuroscience
– volume: 45
  start-page: 555
  year: 2010
  end-page: 566
  article-title: Serotonin receptor signaling and regulation via beta‐arrestins
  publication-title: Critical Reviews in Biochemistry and Molecular Biology
– ident: e_1_2_9_140_1
  doi: 10.1126/science.1232808
– ident: e_1_2_9_61_1
  doi: 10.1038/s41594‐018‐0180‐z
– ident: e_1_2_9_117_1
  doi: 10.1016/S0021‐9258(18)53442‐6
– ident: e_1_2_9_44_1
  doi: 10.1016/j.neuron.2007.01.008
– ident: e_1_2_9_75_1
  doi: 10.1038/nature19112
– ident: e_1_2_9_35_1
  doi: 10.1073/pnas.87.6.2187
– volume: 234
  start-page: 442
  year: 1985
  ident: e_1_2_9_81_1
  article-title: Phasic and tonic components in 5‐HT2 receptor‐mediated rat aorta contraction: Participation of Ca++ channels and phospholipase C
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
  contributor:
    fullname: Nakaki T.
– ident: e_1_2_9_66_1
  doi: 10.1038/nsmb.3014
– ident: e_1_2_9_49_1
  doi: 10.1021/cn400216u
– volume-title: The use of LSD in psychotherapy and alcoholism
  year: 1967
  ident: e_1_2_9_3_1
  contributor:
    fullname: Abramson H. A.
– ident: e_1_2_9_30_1
  doi: 10.1016/j.celrep.2021.109836
– volume: 284
  start-page: 346
  year: 1998
  ident: e_1_2_9_36_1
  article-title: Integration of mitogen‐activated protein kinase kinase activation in vascular 5‐hydroxytryptamine2A receptor signal transduction
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
  contributor:
    fullname: Florian J. A.
– ident: e_1_2_9_130_1
  doi: 10.1074/jbc.M805705200
– ident: e_1_2_9_22_1
  doi: 10.1146/annurev‐biochem‐061620‐044044
– ident: e_1_2_9_33_1
  doi: 10.1016/j.neuron.2021.07.017
– ident: e_1_2_9_137_1
  doi: 10.1523/JNEUROSCI.17-08-02785.1997
– ident: e_1_2_9_37_1
  doi: 10.1016/j.neuropharm.2007.03.013
– ident: e_1_2_9_113_1
  doi: 10.1124/mol.52.2.259
– ident: e_1_2_9_114_1
  doi: 10.1016/S0163‐7258(98)00019‐9
– ident: e_1_2_9_7_1
  doi: 10.1016/0306‐4522(91)90128‐B
– ident: e_1_2_9_111_1
  doi: 10.1016/0028‐3908(84)90244‐2
– ident: e_1_2_9_141_1
  doi: 10.1016/j.cell.2016.12.033
– ident: e_1_2_9_95_1
  doi: 10.1016/j.bcp.2020.114251
– ident: e_1_2_9_99_1
  doi: 10.1016/S0091‐3057(01)00720‐1
– ident: e_1_2_9_93_1
  doi: 10.1016/0306‐4522(87)90327‐7
– ident: e_1_2_9_94_1
  doi: 10.1016/j.cell.2018.01.001
– ident: e_1_2_9_106_1
  doi: 10.1016/0024‐3205(87)90621‐7
– ident: e_1_2_9_98_1
  doi: 10.1002/j.1460-2075.1988.tb03308.x
– ident: e_1_2_9_46_1
  doi: 10.1124/mol.63.5.961
– ident: e_1_2_9_67_1
  doi: 10.2174/1568026023393796
– ident: e_1_2_9_19_1
  doi: 10.3109/10409238.2010.516741
– ident: e_1_2_9_84_1
  doi: 10.1016/S0893‐133X(01)00405‐5
– ident: e_1_2_9_28_1
  doi: 10.1016/S0306‐4522(02)00146‐X
– volume: 19
  start-page: 1164
  year: 1993
  ident: e_1_2_9_55_1
  article-title: The ala/ser242 species variation results in species selectivity with certain substituted ergolines and tryptamines for 5‐HT2 receptors
  publication-title: Society for Neuroscience Abstracts
  contributor:
    fullname: Johnson M. P.
– ident: e_1_2_9_76_1
  doi: 10.1002/syn.890210205
– ident: e_1_2_9_72_1
  doi: 10.1126/science.1190287
– ident: e_1_2_9_92_1
  doi: 10.1016/0006‐8993(85)90857‐1
– volume: 48
  start-page: 230
  year: 1995
  ident: e_1_2_9_39_1
  article-title: 5‐Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation
  publication-title: Molecular Pharmacology
  contributor:
    fullname: Garnovskaya M. N.
– ident: e_1_2_9_109_1
  doi: 10.1016/0165-3806(91)90236-C
– ident: e_1_2_9_13_1
  doi: 10.1016/0306‐9877(91)90077‐C
– ident: e_1_2_9_74_1
  doi: 10.1016/j.celrep.2018.05.022
– volume: 38
  start-page: 594
  year: 1990
  ident: e_1_2_9_131_1
  article-title: 4‐[125I]‐(2,5‐dimethoxy)phenylisopropylamine and [3H]‐ketanserin labeling of 5‐hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected witha rat 5HT2 cDNA: Evidence for multiple states and not multiple 5HT2 receptor subtypes
  publication-title: Molecular Pharmacology
  contributor:
    fullname: Teitler M.
– ident: e_1_2_9_146_1
  doi: 10.1074/jbc.M301905200
– ident: e_1_2_9_27_1
  doi: 10.1002/(SICI)1096‐9861(19990628)409:2<187:AID‐CNE2>3.0.CO;2‐P
– ident: e_1_2_9_122_1
  doi: 10.1016/j.neuron.2021.06.008
– ident: e_1_2_9_89_1
  doi: 10.1016/j.neures.2014.03.006
– volume: 45
  start-page: 1095
  year: 1994
  ident: e_1_2_9_134_1
  article-title: Antagonist‐mediated down‐regulation of 5‐hydroxytryptamine type 2 receptor gene expression: Modulation of transcription
  publication-title: Molecular Pharmacology
  contributor:
    fullname: Toth M.
– ident: e_1_2_9_96_1
  doi: 10.1021/acschemneuro.9b00528
– ident: e_1_2_9_148_1
  doi: 10.1016/j.neures.2011.07.1824
– ident: e_1_2_9_116_1
  doi: 10.1016/j.expneurol.2021.113778
– ident: e_1_2_9_144_1
  doi: 10.1002/(SICI)1098‐2396(199709)27:1<79:AID‐SYN8>3.0.CO;2‐A
– ident: e_1_2_9_63_1
  doi: 10.1523/JNEUROSCI.3007-12.2013
– ident: e_1_2_9_87_1
  doi: 10.1002/syn.10006
– ident: e_1_2_9_10_1
  doi: 10.1016/j.bbrc.2020.08.022
– volume: 45
  start-page: 277
  year: 1994
  ident: e_1_2_9_54_1
  article-title: Species variations in transmembrane region V of the 5‐Hydroxytrptamine type 2A receptor alter the structure‐activity relationship of certain ergolines and tryptamines
  publication-title: Molecular Pharmacology
  contributor:
    fullname: Johnson M. L.
– ident: e_1_2_9_80_1
  doi: 10.1126/science.aat8078
– ident: e_1_2_9_115_1
  doi: 10.1177/107385849900500414
– ident: e_1_2_9_32_1
  doi: 10.1161/CIRCRESAHA.110.231308
– ident: e_1_2_9_26_1
  doi: 10.1016/0028‐3908(84)90017‐0
– ident: e_1_2_9_12_1
  doi: 10.1002/syn.890090311
– volume: 238
  start-page: 480
  year: 1986
  ident: e_1_2_9_112_1
  article-title: 5‐hydroxytryptamine2 receptors coupled to phospholipase‐C in rat aorta ‐ modulation of phosphoinositide turnover by phorbol ester
  publication-title: Journal of Pharmacology and Experimental Therapeutics
  contributor:
    fullname: Roth B.
– ident: e_1_2_9_6_1
  doi: 10.1073/pnas.1104807108
– volume: 10
  start-page: 773
  year: 1996
  ident: e_1_2_9_105_1
  article-title: Highly conserved aromatic residues are essential for agonist efficacy at 5‐HT2A receptors
  publication-title: The FASEB Journal
  contributor:
    fullname: Roth B.
– ident: e_1_2_9_133_1
  doi: 10.1016/0169‐328X(94)90015‐9
– ident: e_1_2_9_29_1
  doi: 10.1016/0006‐2952(84)90699‐3
– ident: e_1_2_9_88_1
  doi: 10.1016/j.cell.2020.03.020
– ident: e_1_2_9_107_1
  doi: 10.1016/0922‐4106(91)90093‐W
– ident: e_1_2_9_77_1
  doi: 10.1016/j.ebiom.2016.08.049
– ident: e_1_2_9_97_1
  doi: 10.7554/eLife.35082
– ident: e_1_2_9_147_1
  doi: 10.1016/S0306‐4522(03)00589‐X
– volume: 3
  start-page: 427
  year: 1990
  ident: e_1_2_9_108_1
  article-title: Regulation of 5‐HT2 and 5‐HT1C serotonin receptor levels
  publication-title: Methodology and Mechanisms. Neuropsychopharmacology
  contributor:
    fullname: Roth B. L.
– ident: e_1_2_9_73_1
  doi: 10.1093/ijnp/pyy047
– ident: e_1_2_9_65_1
  doi: 10.1016/S0006‐3223(98)00132‐2
– ident: e_1_2_9_118_1
  doi: 10.1046/j.1471‐4159.1997.68051998.x
– ident: e_1_2_9_45_1
  doi: 10.1002/(SICI)1097‐4652(199806)175:3<341:AID‐JCP12>3.0.CO;2‐8
– ident: e_1_2_9_56_1
  doi: 10.1073/pnas.0905884106
– ident: e_1_2_9_125_1
  doi: 10.1073/pnas.0600585103
– ident: e_1_2_9_43_1
  doi: 10.1016/0024‐3205(84)90436‐3
– ident: e_1_2_9_48_1
  doi: 10.1111/j.1460‐9568.2005.03968.x
– ident: e_1_2_9_41_1
  doi: 10.1177/0269881114555249
– ident: e_1_2_9_58_1
  doi: 10.1074/mcp.M113.036558
– ident: e_1_2_9_126_1
  doi: 10.1016/0166‐4328(96)00070‐8
– ident: e_1_2_9_57_1
  doi: 10.1073/pnas.87.3.928
– ident: e_1_2_9_21_1
  doi: 10.1126/scisignal.aav0320
– ident: e_1_2_9_110_1
  doi: 10.1111/j.1471-4159.1987.tb02444.x
– ident: e_1_2_9_5_1
  doi: 10.1038/tp.2011.35
– ident: e_1_2_9_123_1
  doi: 10.1124/mol.58.5.877
– ident: e_1_2_9_31_1
  doi: 10.1016/S0021‐9258(20)79672‐9
– ident: e_1_2_9_136_1
  doi: 10.1124/jpet.106.104463
– volume: 43
  start-page: 755
  year: 1993
  ident: e_1_2_9_24_1
  article-title: A single point mutation (Phe340–>Leu340) of a conserved phenylalanine abolishes 4‐[125I]iodo‐(2,5‐dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5‐hydroxytryptamine2 receptors
  publication-title: Molecular Pharmacology
  contributor:
    fullname: Choudhary M. S.
– ident: e_1_2_9_83_1
  doi: 10.1016/S0169‐328X(03)00029‐9
– ident: e_1_2_9_128_1
  doi: 10.1124/jpet.115.229765
– ident: e_1_2_9_52_1
  doi: 10.1124/jpet.117.239905
– ident: e_1_2_9_50_1
  doi: 10.1038/s41386‐020‐00883‐6
– ident: e_1_2_9_23_1
  doi: 10.1016/0169‐328X(92)90005‐V
– ident: e_1_2_9_79_1
  doi: 10.1016/j.neuropharm.2017.01.034
– ident: e_1_2_9_129_1
  doi: 10.1124/mol.109.061440
– volume: 293
  start-page: 735
  year: 2000
  ident: e_1_2_9_64_1
  article-title: A highly conserved aspartic acid (D155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5‐HT2A serotonin receptor but does not participate in activation via a ‘salt‐bridge disruption’ mechanism
  publication-title: Journal of Pharmacology and Experimental Therapeutics
  contributor:
    fullname: Kristiansen K.
– ident: e_1_2_9_135_1
  doi: 10.1074/jbc.M501696200
– volume: 47
  start-page: 450
  year: 1995
  ident: e_1_2_9_25_1
  article-title: Differential ergoline and ergopeptine binding to 5‐hydroxytryptamine2A receptors: Ergolines require an aromatic residue at position 340 for high affinity binding [published erratum appears in Mol Pharmacol 1995 Sep; 48(3):568]
  publication-title: Molecular Pharmacology
  contributor:
    fullname: Choudhary M. S.
– ident: e_1_2_9_82_1
  doi: 10.1046/j.1471‐4159.1996.67062521.x
– ident: e_1_2_9_138_1
  doi: 10.1021/acs.jmedchem.6b00748
– ident: e_1_2_9_70_1
  doi: 10.1016/0014‐2999(87)90373‐6
– ident: e_1_2_9_143_1
  doi: 10.1016/S0223-5234(99)80094-4
– ident: e_1_2_9_16_1
  doi: 10.1146/annurev.med.60.042307.110802
– ident: e_1_2_9_47_1
  doi: 10.1152/ajprenal.1999.276.6.F922
– ident: e_1_2_9_51_1
  doi: 10.1073/pnas.95.2.735
– ident: e_1_2_9_71_1
  doi: 10.1038/272168a0
– ident: e_1_2_9_100_1
  doi: 10.3390/ijms22020835
– ident: e_1_2_9_90_1
  doi: 10.1038/s41589‐020‐0535‐8
– ident: e_1_2_9_60_1
  doi: 10.1016/j.cell.2020.08.024
– ident: e_1_2_9_127_1
  doi: 10.1038/171387a0
– ident: e_1_2_9_8_1
  doi: 10.1016/0306‐4522(90)90099‐P
– ident: e_1_2_9_139_1
  doi: 10.1097/00001756‐199812010‐00024
– ident: e_1_2_9_119_1
  doi: 10.1016/j.tins.2020.11.008
– ident: e_1_2_9_124_1
  doi: 10.1016/S0021‐9258(20)85329‐0
– ident: e_1_2_9_9_1
  doi: 10.1016/S1043-9471(05)80049-7
– ident: e_1_2_9_120_1
  doi: 10.1523/JNEUROSCI.1665-10.2010
– ident: e_1_2_9_103_1
  doi: 10.1016/j.neuron.2016.01.040
– ident: e_1_2_9_17_1
  doi: 10.1074/jbc.M404673200
– ident: e_1_2_9_121_1
  doi: 10.1073/pnas.0708862105
– ident: e_1_2_9_4_1
  doi: 10.1016/S0028‐3908(97)00051‐8
– ident: e_1_2_9_59_1
  doi: 10.1038/nature08506
– ident: e_1_2_9_91_1
  doi: 10.1111/j.1471-4159.2006.04173.x
– ident: e_1_2_9_11_1
  doi: 10.1074/jbc.M312106200
– ident: e_1_2_9_2_1
  doi: 10.1523/JNEUROSCI.1090‐09.2009
– ident: e_1_2_9_40_1
  doi: 10.1097/NMD.0000000000000113
– ident: e_1_2_9_101_1
  doi: 10.1016/j.euroneuro.2016.05.001
– ident: e_1_2_9_142_1
  doi: 10.1126/science.1232807
– ident: e_1_2_9_18_1
  doi: 10.1098/rspb.1983.0093
– ident: e_1_2_9_38_1
  doi: 10.1016/j.euroneuro.2019.10.013
– ident: e_1_2_9_53_1
  doi: 10.1016/0005‐2736(95)00073‐C
– ident: e_1_2_9_14_1
  doi: 10.1111/j.1749‐6632.1998.tb10180.x
– ident: e_1_2_9_132_1
  doi: 10.1016/0166‐4328(96)00093‐9
– ident: e_1_2_9_102_1
  doi: 10.1038/s41598-021-96736-3
– ident: e_1_2_9_34_1
  doi: 10.1126/science.1103492
– ident: e_1_2_9_62_1
  doi: 10.1021/acsptsci.0c00176
– ident: e_1_2_9_15_1
  doi: 10.1124/mol.54.1.94
– ident: e_1_2_9_68_1
  doi: 10.1124/jpet.102.042184
– volume: 38
  start-page: 604
  year: 1990
  ident: e_1_2_9_20_1
  article-title: [3H]‐DOB (4‐bromo‐2,5‐dimethoxyphenylisopropylamine) and [3H]‐ketanserin label two affinity states of the cloned human 5‐hydroxytryptamine2 receptor
  publication-title: Molecular Pharmacology
  contributor:
    fullname: Branchek T.
– ident: e_1_2_9_42_1
  doi: 10.1046/j.1471-4159.1999.0722206.x
– ident: e_1_2_9_85_1
  doi: 10.1124/pr.115.011478
– ident: e_1_2_9_149_1
  doi: 10.1016/j.cell.2021.01.027
– ident: e_1_2_9_69_1
  doi: 10.1111/j.1471‐4159.1983.tb11817.x
– ident: e_1_2_9_86_1
  doi: 10.1016/j.pharmthera.2003.11.002
– ident: e_1_2_9_145_1
  doi: 10.1016/0014‐2999(85)90577‐1
– volume: 280
  start-page: 576
  year: 1997
  ident: e_1_2_9_104_1
  article-title: High‐affinity agonist binding is not sufficient for agonist efficacy at 5‐hydroxytryptamine2A receptors: Evidence in favor of a modified ternary complex model
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
  contributor:
    fullname: Roth B. L.
– ident: e_1_2_9_78_1
  doi: 10.1016/0006-8993(90)90502-3
SSID ssj0016461
Score 2.546927
SecondaryResourceType review_article
Snippet A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid...
Abstract A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 24
SubjectTerms Drugs
G protein‐coupled receptors (GPCR)
Health care
LSD
Lysergic acid diethylamide
Lysergide
Mental health
Mescaline
neurons
Psilocybin
Psychedelic drugs
psychedelics
serotonin
special issue
Title Molecular insights into psychedelic drug action
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjnc.15540
https://www.ncbi.nlm.nih.gov/pubmed/34797943
https://www.proquest.com/docview/2682587240
https://search.proquest.com/docview/2600285567
Volume 162
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFD4MX_TFy-ZlOqWKiC-d6y1t8WlM5xhsD-JgD0JpklZE7GRtH_TXe056wSmC-FICSUmak5N8X3ryBeBcSOZ70nJ1O7albgvP0blAgyAyMX0j4oJJOig8mbLRzB7PnXkDrquzMIU-RL3hRp6h5mty8JCnX50c_YcWQ-LrhuVSONfNfS0dRbJZRq0UjiOzVBVSUTzVm6tr0Q-AuYpX1YIz3ILHqqlFnMlLN894V3x8U3H857dsw2YJRLV-MXJ2oBElTWj1EyThr-_ahaZCQ9WeexPWB9W1cC24mlQX6mrPSUrUPsVEttBU3HQksSVCk8v8SSuOTOzCbHj7MBjp5a0LuiBhGJ2EJj30azOOPMFNGSOAcd0ed2UY9tC0FmIQ17SEj3aMGetFDEmQR9wW0RTOf9YerCWLJDoAzZEOC5GTcBZbthX7foiAI5R-GEuLI3Bpw1nV_8FbIa4R1KQkEYHqkjZ0KssEpX-lgcmQ2XquSdmndTb2BP3uCJNokVMZIpSOw7Ce_cKidS10fpak8dpwqezye_XBeDpQicO_Fz2CDZPGnYrq7cBatsyjY8QuGT9RgxSfd3PjE9l854A
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB5KPdSLj9ZHtWoUES-pbR6bBLyUaqm17UFa6EVCspuIiKm0yUF_vTObB1YRxFtgN-xmZ2f3-zaz3wCcc8EcW-iWaoSGUA1um6rP0SCITDSnHficCbooPBqz_tQYzMxZCa7zuzCpPkRx4EaeIddrcnA6kP7q5ehAtBsiYV9Dd9cpccPNQyEeRcJZ7UIrHOdmpisk43jyV1d3ox8QcxWxyi2ntwmPeWfTSJOXZhL7Tf7xTcfxv1-zBRsZFlU66eTZhlIQVaHWiZCHv74rF4qMDpXH7lWodPPMcDW4GuU5dZXnaEnsfokP8VyRodOBwK5wRSySJyW9NbED097tpNtXs8QLKidtGJW0Jm10bS0MbO5rIkQMY1kt3xKe10Lr6ghDLE3nDpoyZKwVMORBNtFbBFS4BOq7UI7mUbAPiilM5iEt8VmoG3roOB5iDk84Xih0H7FLHc5yA7hvqb6GW_CSiLtySOrQyE3jZi62dDWG5Na2NCo-LYpxJOiPhxcF84TqEKc0TYbt7KUmLVqhK7SkjleHS2mY35t3B-OufDj4e9UTqPQno6E7vBvfH8K6RpNQBvk2oBwvkuAIoUzsH8sZ-wndu-qn
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFD6MCeqLl83LdGoVEV86t17SFp_GdMzphoiDPQilTVoRsRtb-6C_3nPSC04RxLdCUpLmnJN8X3ryBeCUC-bYQrdUIzSEanDbVH2OBkFkojmtwOdM0EHhwZD1RkZ_bI5LcJmfhUn1IYoNN4oMOV9TgE9F-DXIMX5oMUS-vmQwRL6EiB4K7SjSzWoVUuHompmskEzjyV9dXIx-IMxFwCpXnO46POV9TRNNXhtJ7Df4xzcZx39-zAasZUhUaaeuswmlIKpAtR0hC397V84UmRsqN90rsNLJ74WrwsUgv1FXeYnmxO3n-BBPFJk4HQjsCVfELHlW0jMTWzDqXj92emp27YLKSRlGJaVJGwNbCwOb-5oIEcFYVtO3hOc10bY6ghBL07mDhgwZawYMWZBN5BbhFE6A-jaUo0kU7IJiCpN5aBqfhbqhh47jIeLwhOOFQvcRudTgJB9_d5qqa7gFK4m4K4ekBvXcMm4WYHNXY0htbUuj4uOiGEeC_nd4UTBJqA4xStNk2M5OatGiFTpAS9p4NTiXdvm9ebc_7MiHvb9XPYLl-6uue3czvN2HVY1cUGb41qEcz5LgAHFM7B9Kf_0EK2rpVg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+insights+into+psychedelic+drug+action&rft.jtitle=Journal+of+neurochemistry&rft.au=Slocum%2C+Samuel+T&rft.au=DiBerto%2C+Jeffrey+F&rft.au=Roth%2C+Bryan+L&rft.date=2022-07-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0022-3042&rft.eissn=1471-4159&rft.volume=162&rft.issue=1&rft.spage=24&rft.epage=38&rft_id=info:doi/10.1111%2Fjnc.15540&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3042&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3042&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3042&client=summon